Figures & data
Figure 1 Study flow chart previously provided as supporting online information in Ballin et al 2019.Citation27
![Figure 1 Study flow chart previously provided as supporting online information in Ballin et al 2019.Citation27](/cms/asset/db7f4add-6aed-40d7-bcdc-d168be7c3245/dcia_a_213133_f0001_b.jpg)
Table 1 Changes in outcomes during the 10-week study period
Figure 2 Mean changes and 95% confidence intervals for SF-36 raw scores across all subscales and component summaries from baseline to follow-up for the intervention group compared to the control group. P-values are derived from ANCOVA on mean change from baseline to follow-up adjusted for baseline values.
![Figure 2 Mean changes and 95% confidence intervals for SF-36 raw scores across all subscales and component summaries from baseline to follow-up for the intervention group compared to the control group. P-values are derived from ANCOVA on mean change from baseline to follow-up adjusted for baseline values.](/cms/asset/5695a80c-c880-43d2-8470-d0034dfd74a2/dcia_a_213133_f0002_b.jpg)
Figure 3 Mean percentage changes in cardiometabolic risk markers in the study groups following the 10-week intervention period. Error bars represent standard errors of the mean. P-values are derived from ANCOVAs on mean change from baseline to follow-up in percent adjusted for baseline values.
![Figure 3 Mean percentage changes in cardiometabolic risk markers in the study groups following the 10-week intervention period. Error bars represent standard errors of the mean. P-values are derived from ANCOVAs on mean change from baseline to follow-up in percent adjusted for baseline values.](/cms/asset/bd742626-dafa-436f-a679-5b8ca768219f/dcia_a_213133_f0003_b.jpg)